Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDFT1 | P37268 | 18/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4285986 | 1.00 | FDFT1 (0.60) | FDFT1 | |
| SCHEMBL4285992 | 1.00 | FDFT1 (0.60) | FDFT1 | |
| SCHEMBL4300999 | 0.94 | FDFT1 (0.62) | FDFT1 | |
| SCHEMBL4301006 | 0.94 | FDFT1 (0.62) | FDFT1 | |
| SCHEMBL4301000 | 0.94 | FDFT1 (0.62) | FDFT1 | |
| SCHEMBL4292611 | 0.93 | FDFT1 (0.51) | FDFT1 | |
| SCHEMBL4292608 | 0.93 | FDFT1 (0.51) | FDFT1 | |
| SCHEMBL4292617 | 0.93 | FDFT1 (0.51) | FDFT1 | |
| Hydrochloric Acid SCHEMBL4290381 | 0.92 | FDFT1 (0.62) | FDFT1 | |
| Hydrochloric Acid SCHEMBL4290367 | 0.92 | FDFT1 (0.62) | FDFT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090239839-A1 | RECEPTOR ANTAGONIST | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-09-24 | — | — | US | disclosed |
| US-20070129348-A1 | Receptor antagonist | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-06-07 | — | — | US | disclosed |
| EP-1623710-A1 | RECEPTOR ANTAGONIST | Takeda Pharmaceutical Company Limited (JP) | 2006-02-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090239839-A1 | RECEPTOR ANTAGONIST | FSHR, NR0B2, NR4A3 | FDFT1 3077/4885 |
| US-20070129348-A1 | Receptor antagonist | FSHR, NR0B2, NR4A3 | FDFT1 3077/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.